Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) Director Paul J. Mitchell sold 1,000 shares of Alkermes Plc stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $45.90, for a total value of $45,900.00. Following the sale, the director now directly owns 8,000 shares of the company’s stock, valued at approximately $367,200. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of Alkermes Plc (NASDAQ:ALKS) traded up 0.61% during mid-day trading on Monday, hitting $47.75. 697,580 shares of the company’s stock traded hands. Alkermes Plc has a 1-year low of $26.47 and a 1-year high of $54.25. The stock’s 50-day moving average is $44.8 and its 200-day moving average is $43.56. The company’s market cap is $6.901 billion.

Alkermes Plc (NASDAQ:ALKS) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter in the prior year, the company posted $0.40 earnings per share. The company’s quarterly revenue was down 20.3% on a year-over-year basis. On average, analysts predict that Alkermes Plc will post $0.50 earnings per share for the current fiscal year.

A number of research firms have recently commented on ALKS. Analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday. They now have a $50.00 price target on the stock. Finally, analysts at Mizuho upgraded shares of Alkermes Plc from a “neutral” rating to a “buy” rating in a research note on Thursday, April 10th. They now have a $61.00 price target on the stock, up previously from $56.00. Two analysts have rated the stock with a sell rating, five have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $47.00.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.